Northwest Biotherapeutics (NWBO) Common Equity: 2009-2025
Historic Common Equity for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to -$108.6 million.
- Northwest Biotherapeutics' Common Equity fell 35.61% to -$108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.6 million, marking a year-over-year decrease of 35.61%. This contributed to the annual value of -$94.5 million for FY2024, which is 43.66% down from last year.
- Latest data reveals that Northwest Biotherapeutics reported Common Equity of -$108.6 million as of Q3 2025, which was down 8.23% from -$100.4 million recorded in Q2 2025.
- Northwest Biotherapeutics' Common Equity's 5-year high stood at -$56.0 million during Q1 2023, with a 5-year trough of -$1.3 billion in Q3 2023.
- In the last 3 years, Northwest Biotherapeutics' Common Equity had a median value of -$80.1 million in 2024 and averaged -$196.5 million.
- Per our database at Business Quant, Northwest Biotherapeutics' Common Equity tumbled by 1,136.33% in 2023 and then spiked by 94.05% in 2024.
- Quarterly analysis of 5 years shows Northwest Biotherapeutics' Common Equity stood at -$124.0 million in 2021, then declined by 3.32% to -$128.1 million in 2022, then soared by 48.66% to -$65.8 million in 2023, then crashed by 43.66% to -$94.5 million in 2024, then crashed by 35.61% to -$108.6 million in 2025.
- Its Common Equity was -$108.6 million in Q3 2025, compared to -$100.4 million in Q2 2025 and -$99.5 million in Q1 2025.